Kamlesh K. Sankhala, MD

Medical Oncologist, Cedars Sinai Medical Center Director, Precision NextGen Oncology and Research Center
Precision NextGen Oncology and Research Center

Poster(s):

• (P 230) CIRCULATING TUMOR DNA AS AN EARLY INDICATOR OF RESPONSE, PROGRESSION, AND RECURRENCE OF SARCOMAS

• (P 407) PIMICOTINIB IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): LONG-TERM EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES FROM THE PHASE 3 MANEUVER STUDY

• (P 431) INVOKE: A PHASE 1 STUDY OF OKN4395, A FIRST-IN-CLASS EP2/EP4/DP1 TRIPLE PROSTANOID RECEPTOR ANTAGONIST, IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING SARCOMAS

• (P 433) PHASE I DOSE ESCALATION TRIAL OF STX-001, AN LNP SELF-REPLICATING MRNA EXPRESSING IL-12, IN PATIENTS WITH REFRACTORY TUMORS INCLUDING SARCOMAS

• (P 471) COMBINATION CHEMOTHERAPY WITH GEMCITABINE AND PACLITAXEL: A HIGHLY EFFICACIOUS AND BETTER TOLERATED OPTION FOR ANGIOSARCOMA